Dyne Therapeutics (DYN) Cash from Financing Activities (2020 - 2026)

Dyne Therapeutics (DYN) has 7 years of Cash from Financing Activities data on file, last reported at $7.1 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 95.0% year-over-year to $7.1 million in Q1 2026; TTM through Mar 2026 was $756.1 million, a 39.32% increase from a year earlier, with the FY2025 full-year figure at $890.3 million, up 9.93% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $7.1 million, down from $431.0 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for DYN reached as high as $431.0 million in Q4 2025 and fell as low as $18000.0 in Q1 2022.
• Historically, Cash from Financing Activities has averaged $105.8 million across 5 years, with a median of $24.9 million in 2023.
• Across the five-year window, Cash from Financing Activities tumbled 99.99% in 2022 and soared 159983.33% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at $37.2 million in 2022, then tumbled by 99.6% to $147000.0 in 2023, then jumped by 2373.47% to $3.6 million in 2024, then jumped by 11752.72% to $431.0 million in 2025, then slumped by 98.36% to $7.1 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $7.1 million in Q1 2026, $431.0 million in Q4 2025, and $217.3 million in Q3 2025.